Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences, Mayo Expand Agreement to Include GI Cancers and Diseases

NEW YORK (GenomeWeb News) – Exact Sciences today announced it has expanded its collaboration with Mayo Clinic to include all gastrointestinal cancers and diseases, as well as new cancer screening applications of stool- and blood-based testing.

Exact will still have exclusive rights to commercialize products resulting from the new deal, which builds on a 2009 agreement between it and Mayo.

As part of the new agreement, Exact will make upfront, milestone, and royalty payments of an undisclosed amount to Mayo. It also will continue to fund the collaborative work of David Ahlquist, who developed the technology which formed the basis of the original 2009 agreement between the partners.

The collaboration between Exact and Mayo has resulted in the Cologuard biomarker panel for colorectal cancer that is currently in clinical trials and that Exact plans to commercialize after clearance from the US Food and Drug Administration. Exact has previously said that it expects to file for FDA clearance of the test later this year, with a clinical module submitted early in the first quarter of 2013.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.